A low degree of infl ammation has been associated with complications in pregnancies, including preeclampsia (PE). The aim of our study was to determine the serum values of high sensitivity C Reactive Protein (hs-CRP) and Interleukin-6 (IL-6) in the fi rst and second trimesters of pregnancy in pregnant women with risk factors for the development of PE, and to evaluate their relevance for the prediction of this disorder.
Introduction
Preeclampsia (PE) is a multisystemic disorder specifi c to human pregnancy, which remains an important cause of materno-fetal morbidity and mortality, requiring considerable eff orts to fi nd eff ective prevention strategies. Although the etiopathogeny of this syndrome remains unclear, it is certain that PE is triggered by placental factors given that it occurs only in pregnant women, and defi nitive treatment is delivery [1] .
Th ere is an immunological theory that supports trophoblast and spiral artery remodeling alteration by immune cells, determining the release of ischemic placental factors in the systemic maternal circulation. Also, the increase in the levels of angiogenic factors and trophoblastic detritus may play a role in the pathogeny of PE. In addition to these hypotheses, the imbalance between pro-and antiinfl ammatory factors has also been incriminated in the etiopathogeny of this disorder [2] .
Th e factors that generate an infl ammatory response in PE are represented by the activation of circulating leukocytes, the increase of the production of neutrophil activators and complement activity. Th e exposure of endothelial cells to proinfl ammatory cytokines induces an activation of the coagulation system, of platelet aggregation, vasospasm and endothelial activation [3, 4] .
Recent studies have evidenced a small degree of infl ammation in normal pregnancy. It is not yet known to what extent excessive maternal infl ammation causes endothelial dysfunction in patients that subsequently develop PE [5] . Th e most extensively studied infl ammatory markers include C reactive protein (CRP), interleukin 6 (IL-6), interleukin 8 (IL-8), interleukin 10 (IL-10) and tumor necrosis factor alpha (TNF-). Th e available data suggest the role of these in the mechanisms responsible for the development of PE, but are ambiguous regarding their predictive value [4, 6, 7] . CRP is an acute phase reagent and the most sensitive marker of generalized infl ammatory activity in the organism [8, 9] . IL-6 is a multifunctional proinfl ammatory cytokine, produced by vascular endothelial cells, the placenta and leukocytes, with a decisive role in infl ammatory response and the control of T cell diff erentiation in adaptive immunity. IL-6 is also involved in trophoblast proli-feration and invasion and in oxidative stress, being the key circulating marker of endothelial dysfunction [10] [11] [12] .
Th e aim of our study was to determine the serum values of high sensitivity CRP (hs-CRP) and IL-6 in the fi rst and second trimesters of pregnancy in pregnant women with risk factors for the development of PE, and to evaluate their relevance for the prediction of this disorder.
Material and method
We performed a prospective longitudinal study on 120 pregnant women with risk factors for preeclampsia, who presented to the "Dominic Stanca" Clinic of Obstetrics and Gynecology, Cluj-Napoca, Romania, in the period January 2011 -July 2013.
Correspondence to: Daria Maria Pop E-mail: dariagroza@yahoo.com Th e criteria of inclusion in the study were the presence of at least one of the following risk factors: primiparity; a history of preeclampsia in previous pregnancies; a family history of preeclampsia; pregnancy-associated disorders (renal disease, diabetes mellitus, etc.); obstetric history (preeclampsia, fetal hypotrophy, oligoamnios, perinatal mortality, premature detachment of normally inserted placenta); obesity; young age or age over 40 years; low socioeconomic standard.
Th e exclusion criteria were: pregnant women with clinically manifest infections; recent treatment with non-steroidal antiinfl ammatory drugs and corticosteroids (in the last 14 days); chronic autoimmune and infl ammatory diseases.
All patients included in the study signed an informed consent and the study was approved by the Ethics Board of the "Iuliu Hațieganu" University of Medicine and Pharmacy of Cluj-Napoca. Th e study investigated the serum values of hs-CRP and IL-6 in the fi rst trimester of pregnancy (weeks [10] [11] [12] [13] [14] and in the second trimester of pregnancy (weeks [20] [21] [22] [23] [24] . Th e samples were analyzed according to the following study protocol: 3 ml blood were collected on anticoagulant, the plasma was separated by centrifugation for 15 min at 1000 xg. Th e samples were stored in the freezer at -20°C. When processed, they were gradually thawed on ice. Th e samples were processed according to the instructions of the CRP HS ELISA (DRG Instruments GmbH, Germany) and Human IL-6 Quantikine ELISA kits (R&D Systems Europe Ltd., Abingdon OX143NB, UK).
Th e pregnant women were monitored periodically until delivery, and the development of PE or the physiological evolution of pregnancy was assessed. For the diagnosis of PE, we used the classifi cation system proposed by U.S. NMBPEP Working Group 2000, preceded by AGOC: blood pressure values of at least 140/90 mmHg (on 2 examinations minimum 6 h and maximum 7 days apart), proteinuria higher than 30 mg/dl (in 2 urine samples collected 4-6 h apart); high blood pressure and proteinuria occurred after 20 weeks of pregnancy in a pregnant woman that was normotensive prior to pregnancy and were normalized by 12 weeks postpartum.
At the end of the study, the patients were divided into two groups depending on the evolution of pregnancy:
Group I -26 pregnant women who developed preeclampsia: 9 the severe form, and 17 the moderate form. Of the 9 pregnant women with severe preeclampsia, 4 also had intrauterine growth restriction (IUGR).
Group II -94 pregnant women who did not develop preeclampsia and had a physiological evolution of pregnancy.
Statistical analysis
We used the Mann-Whitney test for the comparison of IL-6 and hs-CRP values in the group with preeclampsia compared to the control group. Th e t-test was inadequate in this case, because the IL-6 and hs-CRP values did not have a normal distribution. We used the binary logit model to assess whether IL-6 and hs-CRP values were correlated with the probability of developing preeclampsia. We noted Y = 1 if the patient had preeclampsia and Y = 0 if the patient did not have preeclampsia. Th e t-test was used for the study of the statistical signifi cance of the coeffi cients. We considered that a variable was statistically signifi cant if the associated p value was <0.05. Th e predictive power of the functions used was evaluated using the ROC (Receiver Operating Characteristics) curve. All statistical processings were performed with the STATA 9.1 software (StataCorp, 4905 Lakeway Drive, College Station, Texas 77845 USA).
Results
We observed that patients with preeclampsia have higher mean and median IL-6 and hs-CRP values. Th e diff erences are more signifi cant for hs-CRP. In the second trimester, both IL-6 and hs-CRP values are more signifi cantly increased than in the fi rst trimester.
Predictive signifi cance of IL-6 values in the fi rst trimester
Th e slightly increased IL-6 values in the fi rst trimester are not statistically signifi cant. Th e sign of the coeffi cient is as expected, positive, and is also found in similar studies.
Th e predictive power of IL-6 values in the fi rst trimester is low (AUROC = 0.6277). Combined with the regression result, it shows that a suspicion of preeclampsia based only on IL-6 values in the fi rst trimester is poorly supported.
Predictive signifi cance of IL-6 values in the second trimester
Th e IL-6 value in the second trimester is statistically signifi cant at a 5% threshold. Th e coeffi cient has the expected sign, positive. Consequently, a higher IL-6 value in the 2 nd trimester increases the probability of preeclampsia.
Th e predictive power of IL-6 values in the second trimester is only slightly higher (AUROC = 0.6978) than that of IL-6 values in the fi rst trimester. However, it remains rather low. A diagnosis of preeclampsia cannot be made only based on IL-6 values in the second trimester, predictability being modest. It is recommended to take into consideration other factors to support a serious suspicion of preeclampsia.
Predictive signifi cance of hs-CRP values in the fi rst trimester
Th e hs-CRP value in the fi rst trimester is not statistically signifi cant. Th e coeffi cient has a positive sign, according to previous empirical studies, but because it is insignifi cant, no conclusion regarding the infl uence of hs-CRP in the fi rst trimester on the probability of preeclampsia can be drawn. Th e predictive power of hs-CRP values in the fi rst trimester is moderate (AUROC = 0.6998). Higher hs-CRP values in the fi rst trimester indicate the probability of preeclampsia.
Predictive signifi cance of hs-CRP values in the second trimester
Th e hs-CRP value in the second trimester is statistically signifi cant at a 5% threshold. Increased hs-CRP values in the second trimester indicate a clear risk for the development of preeclampsia. Th e predictive power of hs-CRP values in the second trimester is high (AUROC = 0.7746). Higher hs-CRP values in the second trimester are a serious indicator of the probability of preeclampsia. Th e percentage of correct predictions based on hs-CRP values in the second trimester is about 77%.
Predictive signifi cance of IL-6 and hs-CRP values in the fi rst trimester
In multiple regression analysis, the coeffi cients for IL-6 and hs-CRP in the fi rst trimester also remain statistically insignifi cant. A prediction of preeclampsia based on these results would be poorly supported.
Th e predictability of preeclampsia based on IL-6 and hs-CRP in the fi rst trimester is not very accurate, which confi rms the conclusions derived from regression.
Predictive signifi cance of IL-6 and hs-CRP values in the second trimester
In multiple regression analysis, the coeffi cients for IL-6 and hs-CRP in the second trimester also maintain their statistical signifi cance at a 5% and 10% threshold, respectively.
Th is is a good premise to try a prediction for the development of preeclampsia based on their conjugated values.
Th e predictability of preeclampsia based on IL-6 and hs-CRP in the second trimester is superior to the one based on the same indicators in the fi rst trimester.
Discussion
Th e immune system and infl ammation play an important role in implantation, placentation and labor, and it is known that the pathogenesis of PE is at least in part immunologically mediated. PE is characterized by a proinfl ammatory status at the level of the fetomaternal interface, which determines an orientation towards Th 1 immune response, compared to antiinfl ammatory response in normal pregnancy [5] . Th e clinical interest in infl ammatory markers in pregnancy led to the investigation of the acute phase protein hs-CRP and IL-6 in the fi rst and second trimesters of pregnancy in pregnant women with risk factors for the development of PE.
Our results indicate an increase of serum IL-6 levels in PE compared to normal pregnancy, with more signifi cantly increased values in the second trimester. Similar data were reported by other literature studies which suggest a marked infl ammatory response in PE [13] [14] [15] [16] .
Th e plasma activation of endothelial cells in PE stimulates IL-6 production that is inhibited by vitamin E [17] . Other recent studies suggest that IL-6 levels in the placenta and peripheral blood do not play a signifi cant role in the induction of an immunological imbalance that leads to PE [13, 18] . Th e association of high IL-6 levels with the development of PE has a moderate predictive power only in the second trimester of pregnancy, in the fi rst trimester predictability being reduced.
Currently, it is not known whether IL-6 plays a direct role in the pathogeny of PE or is just a marker of endothelial cell activation. Recently, it has been demonstrated that IL-6 can interfere with the mechanisms of contraction and relaxation at the level of systemic vessels in pregnancy, playing a role in modeling vascular resistance and implicitly blood pressure [19] .
Our study detected increased hs-CRP values in the fi rst and second trimesters of pregnancy in pregnant women who subsequently developed PE, a signifi cant increase of hs-CRP being evidenced in the second trimester. Th e data obtained by Wolf et al. and Tjoa et al., who found increased CRP levels as early as the fi rst trimester in pregnancies that subsequently developed PE, are in accordance with our results [20, 21] . Th ere are also contradictory data resulting from the studies of Savvidou, who found no differences between CRP levels in pregnant women with PE compared to normal pregnancy [4, 22, 23] .
Th e results of our study indicate the association of high hs-CRP levels in the fi rst and second trimesters of pregnancy with the development of PE, the serum hs-CRP values obtained in the second trimester having a higher predictive power. For a better and early prediction of PE, we associated the two infl ammatory markers studied in the fi rst and second trimesters of pregnancy, the predictive power of the conjugated hs-CRP and IL-6 values being higher in the second trimester.
Conclusions
Th e obtained data suggest the presence of a generalized infl ammatory response in patients with PE as early as the fi rst trimester of pregnancy.
Th e evaluation of infl ammatory markers in pregnancy has complex implications regarding the prediction, screening and prophylaxis of PE. Th e increased hs-CRP and IL-6 values in the second trimester of pregnancy are associated with a higher risk to develop PE, the study providing only a modest effi ciency of the prediction capacity. Further investigations of additional factors that might improve the prediction rate are justifi ed in order to develop more accurate screening methods.
